Tag: Maze Therapeutics

Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline

Financial by 0 comments

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the completion of a $115 million […]

Continue Reading →

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

Financial by 0 comments

Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise Partnership Focused on Delivering Targeted Therapies for Genetically Defined Cardiovascular Diseases PALO ALTO, Calif. and SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Maze Therapeutics today […]

Continue Reading →